Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study

International Journal of Drug Policy

Volumn 47, Issue , 2017, Pages 177-186

  Grebely, Jason ^a   Dalgard, Olav ^b,r   Cunningham, Evan B ^a   Hajarizadeh, Behzad ^a   Foster, Graham R ^c   Bruggmann, Philip ^d   Conway, Brian ^e   Backmund, Markus ^f   Robaeys, Geert ^g,h,i   Swan, Tracy ^j   Amin, Janaki ^a,s   Marks, Philippa S ^a   Quiene, Sophie ^a   Applegate, Tanya L ^a   Weltman, Martin ^k   Shaw, David ^l   Dunlop, Adrian ^m   Hellard, Margaret ⁿ   Bruneau, Julie ^o   Midgard, Håvard ^b,r,t   Bourgeois, Stefan ^p   Staehelin, Cornelia ^q   Dore, Gregory J ^a   more..

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d Arud Centres for Addiction Medicine   (Switzerland)

^e VANCOUVER INFECTIOUS DISEASES CENTRE   (Canada)

^f UNIVERSITY OF MUNICH   (Germany)

^g DEPARTMENT OF CARDIOLOGY   (Belgium)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ HASSELT UNIVERSITY   (Belgium)

^j International Network on Hepatitis in Substance Users   (United States)

^k NEPEAN HOSPITAL   (Australia)

^l ROYAL ADELAIDE HOSPITAL   (Australia)

^m UNIVERSITY OF NEWCASTLE   (Australia)

ⁿ BURNET INSTITUTE   (Australia)

^o CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^p ZNA Psychiatric Hospital Stuivenberg   (Belgium)

^q UNIVERSITY OF BERN   (Switzerland)

^r UNIVERSITY OF OSLO   (Norway)

^s MACQUARIE UNIVERSITY   (Australia)

^t OSLO UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

Drug use; HCV treatment; Hepatitis C; PWID

Indexed keywords

OPIATE; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ANEMIA; ARTICLE; AUSTRALIA; CANADA; CONTROLLED STUDY; DECREASED APPETITE; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; DRY SKIN; EUROPE; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; INJECTION SITE ERYTHEMA; INSOMNIA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAMED GROUPS OF PERSONS; NAUSEA; OPIATE SUBSTITUTION TREATMENT; PATIENT COMPLIANCE; PEOPLE WHO INJECT DRUG; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE; VOMITING; CHRONIC HEPATITIS C; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECT; DRUG USE; GENETICS; GENOTYPE; HEPACIVIRUS; MIDDLE AGED; MULTICENTER STUDY; SUBSTANCE ABUSE; VIROLOGY; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; DRUG USERS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; SELF ADMINISTRATION; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL LOAD;

EID: 85019228007     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2017.05.020     Document Type: Article

References (39)

1. AASLD/IDSA. HCV guidance: Recommendations for testing, managing, and treating hepatitis C. Retrieved March 18, 2017 from https://www.hcvguidelines.org/.
2. Alavi, M., Spelman, T., Matthews, G.V., Haber, P.S., Day, C., van Beek I, Walsh, N., Yeung, B., Bruneau, J., Petoumenos, K., Dolan, K., Kaldor, J.M., Dore, G.J., Hellard, M., Grebely, J., on behalf of the ATAHC Study Group, Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: the Australian Trial in Acute Hepatitis C. International Journal of Drug Policy 26:10 (2015), 976–983.
3. Aspinall, E.J., Corson, S., Doyle, J.S., Grebely, J., Hutchinson, S.J., Dore, G.J., et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: A systematic review and meta-analysis. Clinical Infectious Diseases 57:Suppl. 2 (2013), S80–S89.
4. Barua, S., Greenwald, R., Grebely, J., Dore, G.J., Swan, T., Taylor, L.E., Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Annals of Internal Medicine 163 (2015), 215–223.
5. Bruggmann, P., Falcato, L., Dober, S., Helbling, B., Keiser, O., Negro, F., et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. Journal of Viral Hepatitis 15 (2008), 747–752.
6. Bush, K., Kivlahan, D.R., McDonell, M.B., Fihn, S.D., Bradley, K.A., The AUDIT alcohol consumption questions (AUDIT-C): An effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Archives of Internal Medicine 158 (1998), 1789–1795.
7. Castera, L., Forns, X., Alberti, A., Non-invasive evaluation of liver fibrosis using transient elastography. Journal of Hepatology 48 (2008), 835–847.
8. Dalgard, O., Bjoro, K., Hellum, K.B., Myrvang, B., Ritland, S., Skaug, K., et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study. Hepatology 40 (2004), 1260–1265.
9. Dalgard, O., Bjoro, K., Ring-Larsen, H., Bjornsson, E., Holberg-Petersen, M., Skovlund, E., et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 47 (2008), 35–42.
10. Dalgard, O., Bjøro, K., Ring-Larsen, H., Verbaan, H., In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials. European Journal of Gastroenterology & Hepatology 22:5 (2010), 552–556.
11. Darke, S., Ward, J., Hall, W., Heather, N., Wodak, A., The opiate treatment index (OTI) researcher's manual. Technical report number 11, 1991, National Drug and Alcohol Research Centre, Sydney.
12. Desmet, V.J., Gerber, M., Hoofnagle, J.H., Manns, M., Scheuer, P.J., Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 19 (1994), 1513–1520.
13. Dimova, R.B., Zeremski, M., Jacobson, I.M., Hagan, H., Des Jarlais, D.C., Talal, A.H., Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clinical Infectious Diseases 56 (2013), 806–816.
14. Dore, G.J., Hellard, M., Matthews, G.V., Grebely, J., Haber, P.S., Petoumenos, K., et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 138 (2010), 123–135 e121–e122.
15. Dore, G.J., Altice, F., Litwin, A.H., Dalgard, O., Gane, E.J., Shibolet, O., Luetkemeyer, A., Nahass, R., Peng, C., Conway, B., Grebely, J., Howe, A.Y.M., Gendrano, I.N., Chen, E., Huang, H., Dutko, F.J., Nguyen, B., Wahl, J., Barr, E., Robertson, M.N., Platt, H.L., Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy — A Randomized Trial. Annals of Internal Medicine 165:9 (2016), 625–634.
16. EASL, EASL recommendations on treatment of hepatitis C 2016. Journal of Hepatology 66 (2017), 153–194.
17. Grebely, J., Alavi, M., Micallef, M., Dunlop, A.J., Balcomb, A.C., Phung, N., et al. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: The ETHOS study. Addiction 111 (2016), 311–319.
18. Grebely, J., Dore, G.J., Zeuzem, S., Aspinall, R.J., Fox, R., Han, L., McNally, J., Osinusi, A., Brainard, D.M., Subramanian, G.M., Natha, M., Foster, G.R., Mangia, A., Sulkowski, M., Feld, J.J., Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of Phase 3 ASTRAL trials. Clinical Infectious Diseases 63:11 (2016), 1479–1481.
19. Grebely, J., Mauss, S., Brown, A., Bronowicki, J., Puoti, M., Wyles, D., Natha, M., Zhu, Y., Yang, J., Kreter, B., Brainard, D.M., Yun, C., Carr, V., Dore, G.J., Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of Phase 3 ION trials. Clinical Infectious Diseases 63:11 (2016), 1405–1411.
20. Grebely, J., Raffa, J.D., Meagher, C., Duncan, F., Genoway, K.A., Khara, M., et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. Journal of Gastroenterology and Hepatology 22 (2007), 1519–1525.
21. Grebely, J., Robaeys, G., Bruggmann, P., Aghemo, A., Backmund, M., Bruneau, J., et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. International Journal on Drug Policy 26 (2015), 1028–1038.
22. Hajarizadeh, B., Grebely, J., Dore, G.J., Epidemiology and natural history of HCV infection. Nature Reviews Gastroenterology & Hepatology 10 (2013), 553–562.
23. Hellard, M., Sacks-Davis, R., Gold, J., Hepatitis C treatment for injection drug users: A review of the available evidence. Clinical Infectious Diseases 49 (2009), 561–573.
24. Jensen, D.M., Morgan, T.R., Marcellin, P., Pockros, P.J., Reddy, K.R., Hadziyannis, S.J., et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 43 (2006), 954–960.
25. Kielland, K.B., Delaveris, G.J., Rogde, S., Eide, T.J., Amundsen, E.J., Dalgard, O., Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: A longitudinal long-term cohort study. Journal of Hepatology 60 (2014), 260–266.
26. Lawrinson, P., Copeland, J., Indig, D., The brief treatment outcome measure: Opioid maintenance pharmacotherapy (BTOM) manual. NDARC technical report no. 156, 2003, University of New South Wales, Sydney.
27. Litwin, A.H., Kunins, H.V., Berg, K.M., Federman, A.D., Heavner, K.K., Gourevitch, M.N., et al. Hepatitis C management by addiction medicine physicians: Results from a national survey. Journal of Substance Abuse Treatment 33 (2007), 99–105.
28. Mangia, A., Santoro, R., Minerva, N., Ricci, G.L., Carretta, V., Persico, M., et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. New England Journal of Medicine 352 (2005), 2609–2617.
29. Manolakopoulos, S., Deutsch, M.J., Anagnostou, O., Karatapanis, S., Tiniakou, E., Papatheodoridis, G.V., et al. Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C. Liver International 30 (2010), 1454–1460.
30. Meyer, J.P., Moghimi, Y., Marcus, R., Lim, J.K., Litwin, A.H., Altice, F.L., Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic hepatitis C care continuum. International Journal on Drug Policy 26 (2015), 922–935.
31. Murphy, D.G., Willems, B., Deschenes, M., Hilzenrat, N., Mousseau, R., Sabbah, S., Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5′ untranslated region sequences. Journal of Clinical Microbiology 45 (2007), 1102–1112.
32. Myles, A., Mugford, G.J., Zhao, J., Krahn, M., Wang, P.P., Physicians’ attitudes and practice toward treating injection drug users with hepatitis C: Results from a national specialist survey in Canada. Canadian Journal of Gastroenterology 25 (2011), 135–139.
33. Robaeys, G., Grebely, J., Mauss, S., Bruggmann, P., Moussalli, J., De Gottardi, A., et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clinical Infectious Diseases 57:Suppl. 2 (2013), S129–S137.
34. Sasadeusz, J.J., Dore, G., Kronborg, I., Barton, D., Yoshihara, M., Weltman, M., Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. Addiction 106:5 (2010), 977–984.
35. Sylvestre, D.L., Litwin, A.H., Clements, B.J., Gourevitch, M.N., The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. Journal of Substance Abuse Treatment 29 (2005), 159–165.
36. Vezali, E., Aghemo, A., Colombo, M., A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clinical Therapeutics 32 (2010), 2117–2138.
37. Wai, C.T., Greenson, J.K., Fontana, R.J., Kalbfleisch, J.D., Marrero, J.A., Conjeevaram, H.S., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38 (2003), 518–526.
38. WHO, Guidelines for the screening care and treatment of persons with chronic hepatitis C infection. 2016, World Health Organization.
39. Wiessing, L., Ferri, M., Grady, B., Kantzanou, M., Sperle, I., Cullen, K.J., et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: A systematic review of data for scaling up treatment and prevention. PLoS One, 9, 2014, e103345.